One would have to think that the whole thing was an FDA
One would have to think that the whole thing was an FDA slap down, that Nader was going to go on and brag about NASH 700 results and they cancel the call, he's gone on the 24th, all PR with Nader is removed other than the leadership change which mentions they want a CEO that is in the "club" and the FDA sends out another "bitch slap" letter reminding CytoDyn not behave like Pfizer because you are not a member of the "club".
So now we are being good and letting all the PR come out of and be sanctioned by the FDA and Big Pharma. Don't be alarmed if Brazil results are slow, I mean they started the concept of the trial a year ago and only 100,000's have died on Remdesivir since, so there is no urgency to the trial!!!! The longer they drag their feet on any kind of approval, the longer Leronlimab can't be used for Covid in any situation.
1
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
The Incredible Growth of Lockheed Martin Investments Lockheed Martin (NYSE: LMT) has proven to be a robust choice for investors over the past 15 years, consistently outperforming the market with an impressive average annual return of 13.11%. This performance shows the strength of Lockheed Martin in the aerospace and defense sector, making it a noteworthy consideration for...
Continue Reading
BNP Paribas Enhances Asset Recovery Opportunities BNP Paribas' Securities Services business is making significant strides in enhancing asset recovery for its clients by teaming up with Broadridge Financial Solutions, Inc. This strategic partnership aims to leverage Broadridge's global class action solution, which is designed to amplify claims and ensure higher...
Continue Reading
Important Financial Reporting Timeline for Vilniaus Baldai AB Vilniaus Baldai AB is committed to transparency and timely reporting for its investors. As the financial year 2026 approaches, investors can look forward to the scheduled release of crucial financial information that will reflect the company’s performance. This article outlines the key reporting dates for the...
Continue Reading
Understanding Pure Storage's Stock Journey Pure Storage (NYSE: PSTG) has been on a remarkable trajectory over the past decade, outperforming the market with an impressive annualized return of 17.13%. This performance translates to an average annual gain of 4.73% above the overall market. At present, the company's market capitalization stands at an impressive $27.59...
Continue Reading
Water Ways Technologies Inc. Announces Key Share Consolidation Water Ways Technologies Inc. (TSXV: WWT), known for its innovative approach to agricultural technology, has made significant strides in evolving its corporate structure. Recently, the company confirmed the effective date for its long-anticipated share consolidation, which is scheduled to begin trading on the...
Continue Reading
